GÖTEBORG, Sweden--(BUSINESS WIRE)--Regulatory News:
As per November 28, 2014, the total number of shares in Vitrolife AB (publ)(STO:VITR) amounts to 21,710,115, of which Vitrolife itself holds 0 shares. The share capital amounts to SEK 22,144,317.30.
At the beginning of the month the total number of shares in the company amounted to 19,830,936, of which Vitrolife itself held 0 shares. The share capital amounted to SEK 20,227,554.72.
The increase in the number of shares by 1,879,179 during the month of November is due to the non-cash issue of shares with regards to the acquisition of Unisense FertiliTech A/S.
November 28, 2014
VITROLIFE AB (publ)
Thomas Axelsson, CEO
Vitrolife is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on November 28, 2014 at 2:30 p.m.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
Vitrolife is an international medical device Group. The Fertility product area develops, produces and markets medical devices for assisted reproduction. Work is also carried out to enable the use and handling of stem cells for therapeutic purposes.
Vitrolife has about 320 employees and the company’s products are sold in about 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in USA, Australia, France, Italy, United Kingdom, China, Japan, Hungary and Denmark. The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap.
This information was brought to you by Cision http://news.cision.com